Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
Recruiting
N/A
Interventional Study
Breast Cancer With Low to Intermediate HER2 Expression
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 79
- Sex
- Female
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 20 (estimated)
- Sponsor
- University of Rochester · Other
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.
Exclusion Criteria:
* Prior HF, myocardial infarction, or cardiomyopat…
Contacts